REUBEN R. MERLISS; BERNARD AXELROD; JOSEPH FINEBERG; MORRIS MELNIK
This content is PDF only. Please click on the PDF icon to access.
A gold preparation, characterized by slow absorption after intramuscular injection, has recently been studied in the treatment of rheumatoid arthritis. This preparation, aurothioglycolanilide (Lauron, Endo products), has been the subject of three clinical reports, all of them favorable and all pointing out the lesser incidence of toxicity from this compound as compared with the soluble gold preparations.
In 1944, Stengel1 treated 30 cases of rheumatoid arthritis with aurothioglycolanilide and found that three cases became completely arrested, 17 showed marked improvement, seven showed moderate improvement and three showed slight to no improvement.
Robinson2 reported on 55 cases treated with aurothioglycolanilide and
MERLISS RR, AXELROD B, FINEBERG J, et al. CLINICAL EVALUATION OF AUROTHIOGLYCOLANILIDE (LAURON-ENDO) IN RHEUMATOID ARTHRITIS*. Ann Intern Med. 1951;35:352–357. doi: https://doi.org/10.7326/0003-4819-35-2-352
Download citation file:
Published: Ann Intern Med. 1951;35(2):352-357.
Rheumatoid Arthritis, Rheumatology.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use